Page last updated: 2024-11-12
drosocin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
drosocin: amino acid sequence given in first source for drosocin and its precursor; GenBank Z21942 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 16131048 |
CHEMBL ID | 217215 |
MeSH ID | M0218898 |
Synonyms (7)
Synonym |
---|
149924-99-2 |
l-valine, glycyl-l-lysyl-l-prolyl-l-arginyl-l-prolyl-l-tyrosyl-l-seryl-l-prolyl-l-arginyl-l-prolyl-l-threonyl-l-seryl-l-histidyl-l-prolyl-l-arginyl-l-prolyl-l-isoleucyl-l-arginyl- |
glycyl-l-lysyl-l-prolyl-l-arginyl-l-prolyl-l-tyrosyl-l-seryl-l-prolyl-l-arginyl-l-prolyl-l-threonyl-l-seryl-l-histidyl-l-prolyl-l-arginyl-l-prolyl-l-isoleucyl-l-arginyl-l-valine |
gkprpysprptshprpirv |
drosocin |
CHEMBL217215 |
DTXSID50164429 |
Research Excerpts
Overview
Drosocin is a cationic 19 amino acid peptide secreted by Drosophila in response to septic injury.
Excerpt | Reference | Relevance |
---|---|---|
"Drosocin is a 19-mer, cationic antimicrobial peptide from Drosophila melanogaster. " | ( Evaluation of the antibacterial spectrum of drosocin analogues. Bikker, FJ; de Visser, PC; de Vries-van de Ruit, AM; Kaman-van Zanten, WE; Mars-Groenendijk, RH; Noort, D; van Hooft, PA; Voskamp-Visser, I, 2006) | 2.04 |
"Drosocin is a cationic 19 amino acid peptide secreted by Drosophila in response to septic injury. " | ( Conformational studies by NMR of the antimicrobial peptide, drosocin, and its non-glycosylated derivative: effects of glycosylation on solution conformation. Craik, DJ; Hoffmann, R; McManus, AM; Otvos, L, 1999) | 1.99 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (25)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID511695 | Cytotoxicity against human CEM-SS cells infected with HIV1 3B after 6 days by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. |
AID94139 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Klebsiella pneumoniae 79 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID198004 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Staphylococcus enteritidis D5 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID94138 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Klebsiella pneumoniae 22 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID1197604 | Antimicrobial activity against Escherichia coli ATCC 25922 by broth microdilution assay | 2015 | European journal of medicinal chemistry, Mar-06, Volume: 92 | Understanding the importance of glycosylated threonine and stereospecific action of Drosocin, a Proline rich antimicrobial peptide. |
AID9221 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID64242 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli ML-35 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID1197607 | Antimicrobial activity against Salmonella typhimurium ATCC 14028 by broth microdilution assay | 2015 | European journal of medicinal chemistry, Mar-06, Volume: 92 | Understanding the importance of glycosylated threonine and stereospecific action of Drosocin, a Proline rich antimicrobial peptide. |
AID1197605 | Antimicrobial activity against Escherichia coli ATCC 11775 by broth microdilution assay | 2015 | European journal of medicinal chemistry, Mar-06, Volume: 92 | Understanding the importance of glycosylated threonine and stereospecific action of Drosocin, a Proline rich antimicrobial peptide. |
AID482395 | Cytotoxicity against human SH-SY5Y cells at 600 ug/ml after 24 hrs by MTT assay | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14 | Oncocin (VDKPPYLPRPRPPRRIYNR-NH2): a novel antibacterial peptide optimized against gram-negative human pathogens. |
AID198005 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 h of incubation at 37 C in Mueller-Hinton broth against Staphylococcus enteritidis PD1 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID64223 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli D22 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID511694 | Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. |
AID244840 | Minimum inhibitory concentration against Escherichia coli ATCC 11775 strain | 2005 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11 | Biological evaluation of Tyr6 and Ser7 modified drosocin analogues. |
AID64219 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli D21 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID64243 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli O18:K1:H7 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID1197606 | Antimicrobial activity against Escherichia coli ATCC 35218 by broth microdilution assay | 2015 | European journal of medicinal chemistry, Mar-06, Volume: 92 | Understanding the importance of glycosylated threonine and stereospecific action of Drosocin, a Proline rich antimicrobial peptide. |
AID150919 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Pseudomonas aeruginosa ATCC 27853 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID249731 | Percent of intact peptide after 8 hr of digestion in 25% human serum | 2005 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11 | Biological evaluation of Tyr6 and Ser7 modified drosocin analogues. |
AID482394 | Cytotoxicity against human HeLa cells at 600 ug/ml after 24 hrs by MTT assay | 2010 | Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14 | Oncocin (VDKPPYLPRPRPPRRIYNR-NH2): a novel antibacterial peptide optimized against gram-negative human pathogens. |
AID1197608 | Antimicrobial activity against Salmonella typhi Vi+ by broth microdilution assay | 2015 | European journal of medicinal chemistry, Mar-06, Volume: 92 | Understanding the importance of glycosylated threonine and stereospecific action of Drosocin, a Proline rich antimicrobial peptide. |
AID197876 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Staphylococcus aureus G | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID198329 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Salmonella Typhimurium ATCC 14028 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID64216 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Escherichia coli ATCC 25922 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
AID198008 | Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Staphylococcus epidermidis 4 | 2002 | Journal of medicinal chemistry, Sep-26, Volume: 45, Issue:20 | Antimicrobial peptides: synthesis and antibacterial activity of linear and cyclic drosocin and apidaecin 1b analogues. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (37)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (24.32) | 18.2507 |
2000's | 11 (29.73) | 29.6817 |
2010's | 14 (37.84) | 24.3611 |
2020's | 3 (8.11) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 24.31
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.31) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (5.41%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 35 (94.59%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |